Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Rare Disease Treatment Market
Rare Disease Treatment Market Share
- Report ID: GMI3873
- Published Date: Jan 2023
- Report Format: PDF
Rare Disease Treatment Market Share
- Vertex Pharmaceuticals Incorporated
- GlaxoSmithKline plc.
- F. Hoffman-La-Roche Ltd.
- Eli Lilly and Company
- BioMarin
- Bristol-Myers Squibb
- Sanofi
- Pharmacyclics LLC
- Biogen
- Pfizer Inc.
- Novartis AG
- Merck
- Johnson & Johnson
- Bayer AG
- Amgen Inc.
- Alexion Pharmaceuticals
- AstraZeneca plc
- Seagen Inc.
- AbbVie Inc.
are some of the prominent players in the rare disease treatment market. These companies are focusing on new treatment launches and business expansions to increase their consumer base in the global market.
Frequently Asked Questions (FAQ) :
Market size for rare disease treatment reached over USD 195 billion in 2022 and is anticipated to exhibit more than 8.5% CAGR through 2023-2032, due to the increasing drug research and approval.
Rare disease treatment industry share from the non-biologics drug segment is set to register over 10% CAGR through 2023-2032, on account of their immunogenicity and minimal side effects.
Europe rare disease treatment industry size will exceed USD 115.5 billion by 2032, owing to the rising disease burden and the shifting preference toward early disease diagnosis.
Vertex Pharmaceuticals Incorporated, Biogen, Pfizer Inc., Novartis AG, Merck, Johnson & Johnson, Bayer AG, Amgen Inc., Alexion Pharmaceuticals, and AbbVie Inc. are some of the prominent players in the rare disease treatment business.
Rare Disease Treatment Market Scope
×
Get a free sample of
Rare Disease Treatment Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below